CN109223833A - A kind of probiotic composition of prevention and improvement obesity - Google Patents
A kind of probiotic composition of prevention and improvement obesity Download PDFInfo
- Publication number
- CN109223833A CN109223833A CN201710554548.4A CN201710554548A CN109223833A CN 109223833 A CN109223833 A CN 109223833A CN 201710554548 A CN201710554548 A CN 201710554548A CN 109223833 A CN109223833 A CN 109223833A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- prevention
- obesity
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 42
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 30
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 208000008589 Obesity Diseases 0.000 title claims description 20
- 235000020824 obesity Nutrition 0.000 title claims description 20
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 8
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 7
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 7
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract 2
- 230000000996 additive effect Effects 0.000 claims abstract 2
- 241000894006 Bacteria Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 6
- 229920001202 Inulin Polymers 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims 1
- 150000003271 galactooligosaccharides Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 238000009655 industrial fermentation Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 7
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 4
- 241000755889 Christensenellaceae Species 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 241001029854 Christensenellaceae bacterium Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the fat probiotic compositions of a kind of prevention and improvement, the probiotic composition is made of probiotics and food or medically acceptable auxiliary material or additive, it is characterized in that, the probiotics by following parts by weight probiotic group at: 50 parts of lactobacillus plantarum, 20 parts of lactobacillus acidophilus, 15 parts of lactobacillus reuteri, 10 parts of bifidobacterium adolescentis, 5 parts of animal bifidobacteria.Probiotic composition of the present invention has the function of losing weight and fat.
Description
Technical field
The present invention relates to biomedicine fields, are related to the probiotic composition of a kind of prevention and improvement obesity, with specified
Several probiotics forms for material combination.
Background technique
Nearest scientific research discovery, intestinal flora are closely related with obesity.For example, the study found that by the complete phase of gene
The intestinal flora for the identical twin that same but size difference is very big, a side obesity another party is thinner is transplanted respectively to germfree mouse
Afterwards, the mouse weight for receiving overweight people's intestinal flora, which increases rapidly, becomes fat, and receives the small of thinner person's intestinal flora
Mouse weight keeps normal [1].This shows intestinal flora by influencing digestion, absorption and the metabolic process of host to influence host
Weight.
In the flora for influencing host's weight, part bacterium can reduce host by way of improving host metabolism
Weight, such as content of the Akkmensia.mucin bacterium in obese individuals enteron aisle is well below thinner individual；Pass through mouth simultaneously
Clothes feeding Akkmensia.mucin bacterium, the weight of obesity mice can be remarkably decreased and be improved [2].
In addition to this, another bacterium that can obviously control weight, Christensenellaceae are also sent out in the recent period
It is existing.This bacterium has strong heredity, i.e., the content in crowd is very big by hereditation factor, in slender individual enteron aisle
Content is 3-7%, and this bacterium is practically free of in obese individuals enteron aisle, or only extremely micro presence.When giving obesity
When individual suitable Christensenellaceae bacterium, weight is decreased obviously [3].
In conclusion the content and composed structure and host's weight of enterobacteriaceae are closely related, especially by section in enteron aisle
Learn the specific bacteria for confirming that it is acted on, such as Akkmensia.mucin and Christensenellaceae both bacteriums.
But these bacteriums at present can not be directly edible by people, therefore, is adjusted by taking other kinds of, edible probiotics
Intestinal flora moulds good intestinal environment, to be proliferated specific bacterium, including Akkmensia.mucin and
Both bacteriums of Christensenellaceae, so that preventing and treating obesity by adjusting intestinal flora can as one kind
The scheme of energy.
Summary of the invention
Present invention aims at provide the probiotic composition of a kind of prevention and improvement obesity, comprising:
Lactobacillus plantarum, lactobacillus acidophilus, lactobacillus reuteri, bifidobacterium adolescentis, animal bifidobacteria.
In a preferred embodiment, the probiotics parts by weight are respectively as follows: 40-60 parts of lactobacillus plantarum, lactobacillus acidophilus
10-30 parts, 10-20 parts of lactobacillus reuteri, 5-15 parts of bifidobacterium adolescentis, 3-10 parts of animal bifidobacteria.
In a preferred embodiment, the probiotics parts by weight are respectively as follows: 50 parts of lactobacillus plantarum, lactobacillus acidophilus 20
Part, 15 parts of lactobacillus reuteri, 10 parts of bifidobacterium adolescentis, 5 parts of animal bifidobacteria.
In another preferred example, the probiotic composition further includes prebiotics composition.
In another preferred example, the prebiotics include oligofructose, inulin, xylo-oligosaccharide, and oligoisomaltose is low
Poly- galactolipin etc., preferably oligofructose.
Fat method is prevented and treated another object of the present invention is to provide a kind of, comprising:
It gives obese subject and takes above-mentioned probiotic composition.
In a preferred embodiment, every part of the composition containing 5,000,000,000 or more number of viable (CFU), preferable 100
Hundred million or more, more preferably 20,000,000,000 or more, more preferably 30,000,000,000 or more, more preferably 50,000,000,000 or more, more preferably 100,000,000,000 or more.
In a preferred embodiment, the obese subject daily composition.
In another preferred example, the obese subject daily secondary composition.
Other aspects of the invention are apparent to those skilled in the art due to this disclosure
's.
Detailed description of the invention
Fig. 1, young mice take the changes of weight figure after probiotic composition；
Fig. 2, adult mice take the changes of weight figure after probiotic composition；
Fig. 3, adult mice take the variation of probiotic composition visceral fat weight；
Fig. 4, human volunteer take changes of weight after corresponding probiotic composition；
Fig. 5, human volunteer take corresponding probiotic composition rear intestinal bacterium variation.
Specific embodiment
The present inventor finds a kind of probiotic composition prevented and improvement is fat by extensive research.The present invention can
Fabulous is applied to prevention and improvement obesity, great advantageous effect.
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.Unless otherwise stated, otherwise percentage and number are calculated by weight.
Embodiment 1, the young mice for improving high fat diet induction are fat:
3 week old male C57/B6 mouse are divided into two groups, every group 5, are divided into control group high in fat and experimental group high in fat, raise in Shanghai
City's Experimental Animal Center.The high lipid food that unified feeding fat content is 60%, continuous feeding 5 weeks, until 8 week old of mouse (completely at
Year).
Probiotics is mixed according to following ratio: 50 parts of lactobacillus plantarum, 20 parts of lactobacillus acidophilus, Luo Yishi cream bar
15 parts of bacterium, 10 parts of bifidobacterium adolescentis, 5 parts of animal bifidobacteria.Every part of probiotic composition contains the viable bacteria that sum is 5,000,000,000,
Auxiliary material is maltodextrin, and weight 0.2g, with stomach-filling after 0.5ml physiological saline solution, daily progress stomach-filling twice feeding is prebiotic
Bacterium solution.0.2g maltodextrin is perfused in control group high in fat, equally uses 0.5ml physiological saline solution.
Mouse weight is weighed weekly and is recorded, as a result as shown in Figure 1.
Embodiment 2, the adult mice for improving high fat diet induction are fat:
3 week old male C57/B6 mouse are divided into two groups, every group 5, are divided into control group high in fat and experimental group high in fat, raise in Shanghai
City's Experimental Animal Center.The first high lipid food that unified feeding fat content is 60%, continuous feeding 9 weeks, until after 12 week old of mouse,
Continue the identical high lipid food of feeding, wherein one group carries out stomach-filling with probiotic composition, another group of perfusion compares maltodextrin, tool
Body is as follows:
Probiotics is mixed according to following ratio: 50 parts of lactobacillus plantarum, 20 parts of lactobacillus acidophilus, lactobacillus reuteri 15
Part, 10 parts of bifidobacterium adolescentis, 5 parts of animal bifidobacteria.Every part of probiotic composition contains the viable bacteria that sum is 5,000,000,000, auxiliary material
For maltodextrin, weight 0.2g, with stomach-filling after 0.5ml physiological saline solution, daily progress stomach-filling twice feeding probiotics is molten
Liquid.0.2g maltodextrin is perfused in control group high in fat, equally uses 0.5ml physiological saline solution.
Mouse weight is weighed weekly and is recorded, as a result as shown in Figure 2.
At the end of experiment, mouse is put to death with cervical dislocation, and weighs visceral fat weight, as a result as shown in Figure 3.
Embodiment 3, human body take probiotic composition:
Daily primary corresponding probiotic composition, every part of composition contain the viable bacteria that sum is 20,000,000,000 to 10 volunteers.
After 3 months, variation before and after record weight.As a result as shown in figure 4, almost all of subject's weight have it is different degrees of under
Drop.Subject's stool sampl is taken respectively before and after in experiment simultaneously, with second generation high-flux sequence method
(Illumina MiSeq microarray dataset) is measured, and the intestinal flora result of variations of exemplary subject person is as shown in Figure 5.
Bibliography:
[1] Vanessa Ridaura et al, Cultured gut microbiota from twins discordant
For obesity modulate adiposity and metabolic phenotypes in mice, Science,
September 6, 2013.
[2] Amendine Everard et al, Cross-talk between Akkermansia muciniphila
and intestinal epithelium controls diet-induced obesity, PNAS, May 28 2013.
[3] Julia Goodrich et al, Human Genetics Shape the Gut Microbiome, Cell,
November 6,2014.
Claims (10)
1. a kind of prevention and the fat probiotic composition of improvement, the composition is by probiotics and food or medically acceptable
Auxiliary material or additive composition, which is characterized in that the probiotics by following parts by weight probiotic group at:
40-60 parts of lactobacillus plantarum, 10-30 parts of lactobacillus acidophilus, 10-20 parts of lactobacillus reuteri, bifidobacterium adolescentis 5-15
Part, 3-10 parts of animal bifidobacteria.
2. the probiotic composition of a kind of prevention and improvement obesity as described in claim 1, which is characterized in that described is prebiotic
Bacterium by following parts by weight probiotic group at:
50 parts of lactobacillus plantarum, 20 parts of lactobacillus acidophilus, 15 parts of lactobacillus reuteri, 10 parts of bifidobacterium adolescentis, animal bifid
5 parts of bacillus.
3. the probiotic composition of a kind of prevention and improvement obesity as claimed in claim 1 or 2, which is characterized in that except described
Probiotics outside, the composition further includes prebiotics composition.
4. the probiotic composition of a kind of prevention and improvement obesity as claimed in claim 3, which is characterized in that described is prebiotic
First composition includes but is not limited to:
Oligofructose, inulin, xylo-oligosaccharide, oligoisomaltose, galactooligosaccharide.
5. the probiotic composition of a kind of prevention and improvement obesity as described in claim 1-4, which is characterized in that the group
Polymer type is food, health food or drug.
6. the probiotic composition of a kind of prevention and improvement obesity as described in claim 1-4, which is characterized in that the group
Conjunction object is pulvis, granule, tablet, liquid preparation or capsule.
7. the probiotic composition of a kind of prevention and improvement obesity as described in claim 1-4, which is characterized in that the benefit
By industrial fermentation process, respectively individually fermentation is prepared raw bacterium, and the mixture is by through mixing.
8. a kind of method of prevention and improvement obesity, which is characterized in that give individual and take composition described in claim 1.
9. method according to claim 8, which is characterized in that the obesity is as caused by diet.
10. method according to claim 8, which is characterized in that the individual is obese individuals, and its BMI index is big
In equal to 28.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710554548.4A CN109223833A (en) | 2017-07-10 | 2017-07-10 | A kind of probiotic composition of prevention and improvement obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710554548.4A CN109223833A (en) | 2017-07-10 | 2017-07-10 | A kind of probiotic composition of prevention and improvement obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109223833A true CN109223833A (en) | 2019-01-18 |
Family
ID=65082708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710554548.4A Pending CN109223833A (en) | 2017-07-10 | 2017-07-10 | A kind of probiotic composition of prevention and improvement obesity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109223833A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110679949A (en) * | 2019-09-30 | 2020-01-14 | 山东晶辉生物技术有限公司 | Weight-losing composition and preparation method thereof |
| CN110679813A (en) * | 2019-11-13 | 2020-01-14 | 上海英库商务咨询有限公司 | Probiotic health-care beverage for losing weight |
| CN110692885A (en) * | 2019-11-13 | 2020-01-17 | 上海英库商务咨询有限公司 | Probiotic health-care beverage for relieving constipation |
| CN113005060A (en) * | 2021-03-15 | 2021-06-22 | 江南大学 | Application of bifidobacterium adolescentis CCFM1173 in preparation of functional microbial inoculum, food and/or medicament |
| CN113750113A (en) * | 2020-06-01 | 2021-12-07 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN115466687A (en) * | 2021-06-11 | 2022-12-13 | 浙江妙活氏生物科技有限公司 | Composition for reducing body fat content and body weight and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903032A (en) * | 2007-10-26 | 2010-12-01 | 布伦达·E.·穆尔 | Probiotic compositions and methods for inducing and supporting weight loss |
| CN104000066A (en) * | 2013-12-09 | 2014-08-27 | 胡安然 | A diet for alleviating obesity |
| CN104351786A (en) * | 2014-11-18 | 2015-02-18 | 厦门百泉利康生物科技有限公司 | Slimming food for changing lipophilic physique and processing method thereof |
| CN104968780A (en) * | 2012-09-20 | 2015-10-07 | 普洛特拉有限公司 | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| CN105849248A (en) * | 2013-07-18 | 2016-08-10 | 比奥波利斯有限公司 | Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases |
| CN106176833A (en) * | 2016-08-31 | 2016-12-07 | 佛山市艳晖生物科技有限公司 | A kind of prevent and treat diabetes the compound probiotic liquid controlling body weight and preparation method thereof |
-
2017
- 2017-07-10 CN CN201710554548.4A patent/CN109223833A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903032A (en) * | 2007-10-26 | 2010-12-01 | 布伦达·E.·穆尔 | Probiotic compositions and methods for inducing and supporting weight loss |
| CN104968780A (en) * | 2012-09-20 | 2015-10-07 | 普洛特拉有限公司 | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| CN105849248A (en) * | 2013-07-18 | 2016-08-10 | 比奥波利斯有限公司 | Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases |
| CN104000066A (en) * | 2013-12-09 | 2014-08-27 | 胡安然 | A diet for alleviating obesity |
| CN104351786A (en) * | 2014-11-18 | 2015-02-18 | 厦门百泉利康生物科技有限公司 | Slimming food for changing lipophilic physique and processing method thereof |
| CN106176833A (en) * | 2016-08-31 | 2016-12-07 | 佛山市艳晖生物科技有限公司 | A kind of prevent and treat diabetes the compound probiotic liquid controlling body weight and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| M MILLION等: "Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis,Methanobrevibacter smithii and Escherichia coli", 《INTERNATIONAL JOURNAL OF OBESITY》 * |
| M MILLION等: "Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment", 《CITATION: NUTRITION & DIABETES》 * |
| MMILLION等: "Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii", 《INTERNATIONAL JOURNAL OF OBESITY》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110679949A (en) * | 2019-09-30 | 2020-01-14 | 山东晶辉生物技术有限公司 | Weight-losing composition and preparation method thereof |
| CN110679813A (en) * | 2019-11-13 | 2020-01-14 | 上海英库商务咨询有限公司 | Probiotic health-care beverage for losing weight |
| CN110692885A (en) * | 2019-11-13 | 2020-01-17 | 上海英库商务咨询有限公司 | Probiotic health-care beverage for relieving constipation |
| CN113750113A (en) * | 2020-06-01 | 2021-12-07 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN113750113B (en) * | 2020-06-01 | 2022-12-02 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN113005060A (en) * | 2021-03-15 | 2021-06-22 | 江南大学 | Application of bifidobacterium adolescentis CCFM1173 in preparation of functional microbial inoculum, food and/or medicament |
| CN115466687A (en) * | 2021-06-11 | 2022-12-13 | 浙江妙活氏生物科技有限公司 | Composition for reducing body fat content and body weight and application thereof |
| CN115466687B (en) * | 2021-06-11 | 2024-05-17 | 浙江妙活氏生物科技有限公司 | Composition for reducing body fat content and body weight and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110151796B (en) | Probiotics and prebiotics composition capable of forming lean body mass and application thereof | |
| CN109223833A (en) | A kind of probiotic composition of prevention and improvement obesity | |
| Hitch et al. | Microbiome-based interventions to modulate gut ecology and the immune system | |
| Markowiak et al. | Effects of probiotics, prebiotics, and synbiotics on human health | |
| Guarner | Enteric flora in health and disease | |
| Cardelle-Cobas et al. | Galactooligosaccharides derived from lactose and lactulose: influence of structure on Lactobacillus, Streptococcus and Bifidobacterium growth | |
| Woodmansey | Intestinal bacteria and ageing | |
| CN107019701B (en) | Methods of using human milk oligosaccharides to reduce the incidence of necrotizing enterocolitis in infants, toddlers, or children | |
| AU2012213576B2 (en) | Bifidobacterium bifidum strains for application in gastrointestinal diseases | |
| CN110913879A (en) | Use of lactic acid bacteria for treating or preventing at least one of postpartum depression and postpartum anxiety | |
| WO2017057718A1 (en) | Food and drink product containing poorly digestible compound and colonic-hydrogen-gas producing agent | |
| CN104968780A (en) | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions | |
| AU2012213576A1 (en) | Bifidobacterium bifidum strains for application in gastrointestinal diseases | |
| CN103763940A (en) | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota | |
| TW201703778A (en) | Bifidobacteria as probiotic foundation species of gut microbiota | |
| KR20190116248A (en) | New Probiotic Bifidobacterium Strains | |
| Kumari et al. | Probiotics, prebiotics, and synbiotics: Current status and future uses for human health | |
| CN106659226A (en) | Prebiotics for reducing the risk of obesity later in life | |
| CN106994134B (en) | Application of intestinal probiotics in prevention and/or treatment of diabetes and related diseases thereof | |
| CN109561723A (en) | For preventing, treating the alimentation composition and infant formula of the mixture comprising oligosaccharide and optionally bifidobacterium lactis of non-rotavirus induced diarrhea or reduction its severity | |
| Douglas et al. | Evidence based selection of probiotic strains to promote astronaut health or alleviate symptoms of illness on long duration spaceflight missions | |
| Tulk et al. | Daily consumption of a synbiotic yogurt decreases energy intake but does not improve gastrointestinal transit time: a double-blind, randomized, crossover study in healthy adults | |
| WO2021103776A1 (en) | Compound preparation having auxiliary effect of preventing and treating psychological depression in children and adolescents | |
| CN112273657A (en) | Probiotic composition for preventing or improving allergic diseases, preparation method and application | |
| CN109223831A (en) | A kind of multifarious probiotic composition of raising intestinal flora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190118 |